. 2011 Jun 9;469(11):3190–3199. doi: 10.1007/s11999-011-1939-2

Table 1.

Migrated cell numbers in Transwell® cell migration/invasion assays

Treatment	Dead cells (%)
Treatment	OS-II (n = 10)	OS-III (n = 12)	MG-63
Control	19.25 ± 2.52	27.63 ± 3.40*	25.38 ± 3.15
BQ788 (1 μmol/L)	18.33 ± 2.24^{‡,§,∥,#,¶}	25.92 ± 3.16^{‡,§,∥,#,¶,}*	22.84 ± 2.09
BQ123 (1 μmol/L)	12.89 ± 1.57^†,§,∥,#	15.03 ± 2.26^†,§,∥,#	17.9 2± 1.63
ET-1 (10 pmol/L)	24.95 ± 3.63^{†,‡,∥,#,¶}	35.48 ± 4.75^{†,‡,∥,#,¶,}*	32.35 ± 4.26
ET-1 (100 pmol/L)	37.82 ± 4.97^{†,‡,§,#,¶}	46.25 ± 5.04^{†,‡,§,#,¶}	43.86 ± 5.75
ET-1 (100 pmol/L) + BQ123 (100 pmol/L)	18.85 ± 2.13^‡,§,∥,f	26.80 ± 3.36^{‡,§,∥,f,}*	25.34 ± 2.81
ET-1 (100 pmol/L) + BQ123 (1 μmol/L)	14.75 ± 1.51^†,§,∥,#	17.80 ± 2.03^†,§,∥,#	18.34 ± 1.75

^†p < 0.05 compared with control; ^‡p < 0.05 compared with BQ123 (1 μmol/L); ^§p < 0.05 compared with ET-1 (10 pmol/L); ^∥p < 0.05 compared with ET-1 (100 pmol/L); ^#p < 0.05 compared with ET-1 (100 pmol/L) + BQ123 (100 pmol/L); ^¶p < 0.05 compared with ET-1 (100 pmol/L) + BQ123 (1 μmol/L); *p < 0.05 compared with OS-II group; OS-II = Stage II osteosarcoma; OS-III = Stage III osteosarcoma.